|
1
|
Cripe LD: Adult acute leukemia. Curr Probl
Cancer. 21:1–64. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bloomfield CD and Brunning RD: The revised
French- American-British classification of acute myeloid leukemia:
Is new better? Ann Intern Med. 103:614–616. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grignani F, Ferrucci PF, Testa U, Talamo
G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C,
Nicoletti I, et al: The acute promyelocytic leukemia-specific
PML-RAR alpha fusion protein inhibits differentiation and promotes
survival of myeloid precursor cells. Cell. 74:423–431. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen Z, Tong JH, Dong S, Zhu J, Wang ZY
and Chen SJ: Retinoic acid regulatory pathways, chromosomal
translocations, and acute promyelocytic leukemia. Genes Chromosomes
Cancer. 15:147–156. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Masetti R, Vendemini F, Zama D, Biagi C,
Gasperini P and Pession A: All-trans retinoic acid in the treatment
of pediatric acute promyelocytic leukemia. Expert Rev Anticancer
Ther. 12:1191–1204. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cicconi L, Divona M, Ciardi C, Ottone T,
Ferrantini A, Lavorgna S, Alfonso V, Paoloni F, Piciocchi A,
Avvisati G, et al: PML-RARalpha kinetics and impact of FLT3-ITD
mutations in newly diagnosed acute promyelocytic leukaemia treated
with ATRA and ATO or ATRA and chemotherapy. Leukemia. 30:1987–1992.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gallagher RE, Moser BK, Racevskis J, Poiré
X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D,
Schachter-Tokarz E, Zhou DC, et al: Treatment-influenced
associations of PML-RARalpha mutations, FLT3 mutations, and
additional chromosome abnormalities in relapsed acute promyelocytic
leukemia. Blood. 120:2098–2108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Z-Y and Chen Z: Acute promyelocytic
leukemia: From highly fatal to highly curable. Blood.
111:2505–2515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Caprodossi S, Pedinotti M, Amantini C,
Santoni G, Minucci S, Pelicci PG and Fanelli M: Differentiation
response of acute promyelocytic leukemia cells and PML/RARa
leukemogenic activity studies by real-time RT-PCR. Mol Biotechnol.
30:231–238. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xiao R and Zhang R: Combined analysis on
morphology, immunology, cytogenetics and molecular biology (MICM)
classification of 55 patients with acute promyelocytic leukemia.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 12:147–150. 2004.(In Chinese).
PubMed/NCBI
|
|
11
|
Adams J and Nassiri M: Acute Promyelocytic
Leukemia: A review and discussion of variant translocations. Arch
Pathol Lab Med. 139:1308–1313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choudhury AR, Ju Z, Djojosubroto MW,
Schienke A, Lechel A, Schaetzlein S, Jiang H, Stepczynska A, Wang
C, Buer J, et al: Cdkn1a deletion improves stem cell function and
lifespan of mice with dysfunctional telomeres without accelerating
cancer formation. Nat Genet. 39:99–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ye Q, Shieh JH, Morrone G and Moore MAS:
Expression of constitutively active Notch4 (Int-3) modulates
myeloid proliferation and differentiation and promotes expansion of
hematopoietic progenitors. Leukemia. 18:777–787. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shirley CM, Chu SH, Yang Y, Wright GW,
Staudt LM and Small D: Genetic and pharmacologic Notch4 inhibition
synergizes with FLT3 tyrosine kinase inhibition in vitro to more
effectively eliminate FLT3/ITD-positive leukemia cells. Blood.
124:3583. 2014.PubMed/NCBI
|
|
15
|
Pancewicz J and Nicot C: Current views on
the role of Notch signaling and the pathogenesis of human leukemia.
BMC Cancer. 11:5022011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gilliland DG and Griffin JD: The roles of
FLT3 in hematopoiesis and leukemia. Blood. 100:1532–1542. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Callens C, Chevret S, Cayuela JM, Cassinat
B, Raffoux E, de Botton S, Thomas X, Guerci A, Fegueux N, Pigneux
A, et al: Prognostic implication of FLT3 and Ras gene mutations in
patients with acute promyelocytic leukemia (APL): A retrospective
study from the European APL Group. Leukemia. 19:1153–1160. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Barragan E, Montesinos P, Camos M,
González M, Calasanz MJ, Román-Gómez J, Gómez-Casares MT, Ayala R,
López J, Fuster Ó, et al: Prognostic value of FLT3 mutations in
patients with acute promyelocytic leukemia treated with all-trans
retinoic acid and anthracycline monochemotherapy. Haematologica.
96:1470–1477. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chillon MC, Santamaria C, Garcia-Sanz R,
Balanzategui A, Sarasquete ME, Alcoceba M, Marín L, Caballero MD,
Vidriales MB, Ramos F, et al: Long FLT3 internal tandem
duplications and reduced PML-RARalpha expression at diagnosis
characterize a high-risk subgroup of acute promyelocytic leukemia
patients. Haematologica. 95:745–751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gale RE, Hills R, Pizzey AR, Kottaridis
PD, Swirsky D, Gilkes AF, Nugent E, Mills KI, Wheatley K, Solomon
E, et al: Relationship between FLT3 mutation status, biologic
characteristics, and response to targeted therapy in acute
promyelocytic leukemia. Blood. 106:3768–3776. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fleischmann M, Schnetzke U, Schrenk KG,
Schmidt V, Sayer HG, Hilgendorf I, Hochhaus A and Scholl S: Outcome
of FLT3-ITD-positive acute myeloid leukemia: Impact of allogeneic
stem cell transplantation and tyrosine kinase inhibitor treatment.
J Cancer Res Clin Oncol. 143:337–345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pemmaraju N, Kantarjian H, Ravandi F,
Nogueras-Gonzalez GM, Huang X, O'Brien S, Wierda W, Garcia-Manero
G, Thomas D, Pierce S, et al: Patient characteristics and outcomes
in adolescents and young adults (AYA) with acute myeloid leukemia
(AML). Clin Lymphoma Myeloma Leuk. 16(213–222): e2122016.
|
|
23
|
Hong SD, Kim YK, Kim HN, Lee SR, Ahn JS,
Yang DH, Lee JJ, Lee IK, Shin MG and Kim HJ: Treatment outcome of
all-trans retinoic acid/anthracycline combination chemotherapy and
the prognostic impact of FLT3/ITD mutation in acute promyelocytic
leukemia patients. Korean J Hematol. 46:24–30. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lou Y, Ma Y, Suo S, Ni W, Wang Y, Pan H,
Tong H, Qian W, Meng H, Mai W, et al: Prognostic factors of
patients with newly diagnosed acute promyelocytic leukemia treated
with arsenic trioxide-based frontline therapy. Leuk Res.
39:938–944. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Faisham WI, Saad Mat AZ, Alsaigh LN, Azman
Nor MZ, Imran Kamarul M, Biswal BM, Bhavaraju VM, Salzihan MS,
Hasnan J, Ezane AM, et al: Prognostic factors and survival rate of
osteosarcoma: A single-institution study. Asia Pac J Clin Onco.
13:e104–e110. 2017. View Article : Google Scholar
|
|
26
|
Seifert J, Selle A, Flieger C and Günther
KP: Compliance as a prognostic factor in the treatment of
idiopathic scoliosis. Orthopäde. 38:151–158. 2009. View Article : Google Scholar
|
